CTOs on the Move

VedeqSA Inc

www.vedeqsainc.com

 
VedeqSA Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Planned Parenthood North Central States

Planned Parenthood North Central States (PPNCS) and its subsidiary organizations provide, promote, and protect reproductive and sexual health through high quality care, education and advocacy. A member of America`s most trusted reproductive health care provider, our affiliate is proud to support and operate 29 health centers across our five-state region (Iowa, Minnesota, Nebraska, North Dakota and South Dakota). Each year, we provide health care to nearly 115,000 people and health education to more than 99,000 people in our region.

Kindbody

Kindbody is reinventing healthcare for the modern family, starting with fertility, family-building and wellness benefits. Through a national network of locations, Kindbody is bringing together clinical excellence, best-in-class technology, and accessible pricing — connecting the full patient experience in one, intuitive platform.

Southern Veterinary Partners

Want to sell your vet hospital? We are a veterinarian-owned and managed network of animal hospitals for veterinarians who wish to sell their veterinary practice. Offering veterinary career opportunities. Call 205-453-4760 today!

Laxai

Laxai is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.